ICPT raised $250mn from a 4/4/18 stock offering MC = $1.8Bn Offering will not cover R&D thru EOY. Ocaliva is presently approved for a cholestatic disease known as Primary Biliary Cholangitis (PBC). NASH is an inflammatory cholestatic disease. presently enrolling Ph3 NASH & Ph2 Biliary Artresia